New Dual-Acting Molecules Pair PARP Inhibition with Ferroptosis to Fight TNBC
- Medicinal chemists designed single small molecules combining PARP inhibition with GPX4 inhibition, pairing DNA-repair blockade with ferroptosis induction in one compound rather than as a drug combination.
- Structure-activity relationship work identified a new dual-acting chemotype optimized for potency against both targets.
- Lead compounds showed antitumor activity in triple-negative breast cancer models, supporting the dual-mechanism approach as a possible way to broaden PARP inhibitor efficacy.
💡 Points
Most TNBC is BRCA-wild-type, so PARP monotherapy has nowhere to go without synthetic lethality — pairing it with GPX4 inhibition to force ferroptosis is a real way around that, not just an add-on. The tougher ask is holding potency at two unrelated targets in one scaffold without MW/logP creeping past drug-like — if they pulled that off cleanly, it's more interesting than the biology.
Discovery of Dual PARP/GPX4 Inhibitors for the Treatment of Triple-Negative Breast Cancer ↗